42532 Federal Register / Vol. 78, No. 136 / Tuesday, July 16, 2013 / Notices 

their retinal illumination output) and 

will accept a near IR CCD camera 

connected to a TV mounted on the 

photographic-camera port. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404. The 

prospective exclusive license may be 

granted unless, within fifteen (15) days 

from the date of this published notice, 

NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: July 9, 2013. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2013–16950 Filed 7–15–13; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Start-Up 

Exclusive Evaluation Option License: 

Methods of Treating Giardiasis Using 

Available Compounds 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209 and 37 CFR part 404, 

that the National Institutes of Health 

(NIH), Department of Health and Human 

Services, is contemplating the grant of a 

start-up exclusive evaluation option 

license to practice the inventions 

embodied in U.S. provisional 

Applications 61/392,096 (E–211–2010/ 

0–US–01) filed October 12, 2010 and 

61/411,509 filed November 9, 2010 (E– 

211–2010/1–US–01); PCT application 

No. PCT/US2011/055902 filed October 

12, 2011 (E–211–2010/2–PCT–01); US 

patent application No. 13/878,832 filed 

April 11, 2013 (E–211–2010/2–US–06); 

European patent application No. 

11773158.8 filed May 2, 2013 (E–211– 

2010/2–EP–04); Canadian application 

No. 2,814,694 filed April 11, 2013 (E– 

211–2010/2–CA–03); Australia 

application No. 2011316657 filed April 

12, 2013 (E–211–2010/2–AU–02); and 

Indian application No. 1137/KOLNP/ 

2013 filed April 22, 2013 (E–211–2010/ 

2–IN–05); each entitled ‘‘Methods of 

Treating Giardiasis’’ by Wei Zheng et al. 

to BrioMed, Inc., having a place of 

business at 1743 S. Westgate Ave, Los 

Angeles, CA 90025 USA. The patent 

rights in this invention have been 

assigned to the United States of America 

and the University of Maryland. 

DATES: Only written comments and/or 

application for a license that are 

received by the NIH Office of 

Technology Transfer on or before July 

31, 2013 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Tedd Fenn, Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Email: 

Tedd.Fenn@mail.nih.gov; Telephone: 

301–435–5031; Facsimile: 301–402– 

0220. 

SUPPLEMENTARY INFORMATION: The 

prospective start-up exclusive 

evaluation option license will be royalty 

bearing and will comply with the terms 

and conditions of 35 U.S.C. 209 and 37 

CFR part 404. The prospective start-up 

exclusive evaluation option license may 

be granted unless, within fifteen (15) 

days from the date of this published 

Notice, NIH receives written evidence 

and argument that establishes that the 

grant of the license would not be 

consistent with the requirements of 35 

U.S.C. 209 and 37 CFR part 404. 

This technology includes a group of at 

least twenty-nine, diverse, commercially 

available compounds that are newly 

identified for activity against Giardia 

lamblia parasites. At least six of the 

candidate compounds, Bortezomib, 

Decitabine, Hydroxocobalamin, 

Amlexanox, Idarubicin, and Auranofin 

have preexisting FDA approval for 

human use for other (non-Giardia) 

conditions. Another three compounds, 

Fumagillin, Nitarsone and Carbadox 

have preexisting approval for veterinary 

use for non-Giardia conditions. 

Additional active compounds identified 

include: Acivicin, Riboflavin butyrate, 

BTO–1, GW9662, Dinitroph-dfgp, 

Deserpidine, Tetramethylthiuram 

disulsulfide, Disulfiram, Mitoxantrone, 

Ecteinascidin 743, 17- 

allyaminogeldanamycin, Carboquone 

and Nocodazole. The anti-Giardial 

activity of these compounds presents a 

cost saving opportunity for the rapid 

development of new, better tolerated 

treatments for the most prevalent 

human intestinal parasite infection in 

the United States and the world. 

The proposed field of exclusivity may 

be limited to therapeutics for treatment 

of Giardia infection in mammals. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: July 9, 2013. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer. 

[FR Doc. 2013–16948 Filed 7–15–13; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Cooperative Research and 

Development Agreement (CRADA) 

Opportunity With the Department of 

Homeland Security for the 

Development of a Foot-and-Mouth 

Disease 3ABC ELISA Diagnostic Kit; 

Correction 

AGENCY: Science and Technology 

Directorate, Plum Island Animal Disease 

Center, Department of Homeland 

Security. 

ACTION: Notice of intent; correction. 

SUMMARY: The Department of Homeland 

Security Science and Technology 

Directorate (DHS S&T), through its Plum 

Island Animal Disease Center (PIADC), 

published a document in the Federal 

Register of May 16, 2013, seeking 

industry collaborators to aid DHS S&T 

in developing and validating an ELISA 

diagnostic kit for detection of Foot and 

Mouth Disease Virus (FMDV) nonstructural proteins. The document did 

not specify dates for when the 

submission of proposals are due. 

FOR FURTHER INFORMATION CONTACT: 

Angela Ervin, 202–254–5624. 

Correction 

In the Federal Register of May 16, 

2013, in FR Doc. DHS–2013–0036, on 

page 1, in the third column, correct the 

DATES caption to read: 

DATES: Submit proposals on or before 

August 8, 2013. 

Correction 

In the Federal Register of May 16, 

2013, in FR Doc. DHS–2013–0036, on 


emcdonald on DSK67QTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 136 / Tuesday, July 16, 2013 / Notices 42533 

page 1, in the third column, correct the 

ADDRESSES caption to read: 

ADDRESSES: Mail comments and 

requests to participate to Dr. Angela 

Ervin, (ATTN: Angela Ervin, 245 

Murray Lane SW., Washington, DC 

20528–0075). Submit electronic 

proposals, along with comments and 

other data to Angela.Ervin@hg.dhs.gov 

on or before August 8, 2013. 

Dated: July 8, 2013. 

James Johnson, 

Director, Office of National Laboratories. 

[FR Doc. 2013–16952 Filed 7–15–13; 8:45 am] 

BILLING CODE 9910–9F–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[USCG–2013–0133] 

Collection of Information Under 

Review by Office of Management and 

Budget 

AGENCY: Coast Guard, DHS. 

ACTION: Thirty-day notice requesting 

comments. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995 the 

U.S. Coast Guard is forwarding an 

Information Collection Request (ICR), 

abstracted below, to the Office of 

Management and Budget (OMB), Office 

of Information and Regulatory Affairs 

(OIRA), requesting an revision of a 

currently approved collection of 

information: 1625–0056; Labeling 

Required In 33 CFR parts 181 and 183 

and 46 CFR 25.10–3. Our ICR describes 

the information we seek to collect from 

the public. Review and comments by 

OIRA ensure we only impose paperwork 

burdens commensurate with our 

performance of duties. 

DATES: Comments must reach the Coast 

Guard and OIRA on or before August 15, 

2013. 

ADDRESSES: You may submit comments 

identified by Coast Guard docket 

number [USCG–2013–0133] to the 

Docket Management Facility (DMF) at 

the U.S. Department of Transportation 

(DOT) and/or to OIRA. To avoid 

duplicate submissions, please use only 

one of the following means: 

(1) Online: (a) To Coast Guard docket 

at http://www.regulations.gov. (b) To 

OIRA by email via: OIRAsubmission@omb.eop.gov. 

(2) Mail: (a) DMF (M–30), DOT, West 

Building Ground Floor, Room W12–140, 

1200 New Jersey Avenue SE., 

Washington, DC 20590–0001. (b) To 

OIRA, 725 17th Street NW., 

Washington, DC 20503, attention Desk 

Officer for the Coast Guard. 

(3) Hand Delivery: To DMF address 

above, between 9 a.m. and 5 p.m., 

Monday through Friday, except Federal 

holidays. The telephone number is 202– 

366–9329. 

(4) Fax: (a) To DMF, 202–493–2251. 

(b) To OIRA at 202–395–6566. To 

ensure your comments are received in a 

timely manner, mark the fax, attention 

Desk Officer for the Coast Guard. 

The DMF maintains the public docket 

for this Notice. Comments and material 

received from the public, as well as 

documents mentioned in this Notice as 

being available in the docket, will 

become part of the docket and will be 

available for inspection or copying at 

room W12–140 on the West Building 

Ground Floor, 1200 New Jersey Avenue 

SE., Washington, DC, between 9 a.m. 

and 5 p.m., Monday through Friday, 

except Federal holidays. You may also 

find the docket on the Internet at 

http://www.regulations.gov. 

A copy of the ICR is available through 

the docket on the Internet at http:// 

www.regulations.gov. Additionally, 

copies are available from: Commandant 

(CG–611), ATTN: Paperwork Reduction 

Act Manager, U.S. Coast Guard, 2100 

2nd St. SW., STOP 7101, Washington, 

DC 20593–7101. 

FOR FURTHER INFORMATION CONTACT: 

Contact Mr. Anthony Smith, Office of 

Information Management, telephone 

202–475–3532 or fax 202–475–3929, for 

questions on these documents. Contact 

Ms. Barbara Hairston, Program Manager, 

Docket Operations, 202–366–9826, for 

questions on the docket. 

SUPPLEMENTARY INFORMATION: 

Public Participation and Request for 

Comments 

This Notice relies on the authority of 

the Paperwork Reduction Act of 1995; 

44 U.S.C. Chapter 35, as amended. An 

ICR is an application to OIRA seeking 

the approval, extension, or renewal of a 

Coast Guard collection of information 

(Collection). The ICR contains 

information describing the Collection’s 

purpose, the Collection’s likely burden 

on the affected public, an explanation of 

the necessity of the Collection, and 

other important information describing 

the Collection. There is one ICR for each 

Collection. 

The Coast Guard invites comments on 

whether this ICR should be granted 

based on the Collection being necessary 

for the proper performance of 

Departmental functions. In particular, 

the Coast Guard would appreciate 

comments addressing: (1) The practical 

utility of the Collection; (2) the accuracy 

of the estimated burden of the 

Collection; (3) ways to enhance the 

quality, utility, and clarity of 

information subject to the Collection; 

and (4) ways to minimize the burden of 

the Collection on respondents, 

including the use of automated 

collection techniques or other forms of 

information technology. These 

comments will help OIRA determine 

whether to approve the ICR referred to 

in this Notice. 

We encourage you to respond to this 

request by submitting comments and 

related materials. Comments to Coast 

Guard or OIRA must contain the OMB 

Control Number of the ICR. They must 

also contain the docket number of this 

request, [USCG 2013–0133], and must 

be received by August 15, 2013. We will 

post all comments received, without 

change, to http://www.regulations.gov. 

They will include any personal 

information you provide. We have an 

agreement with DOT to use their DMF. 

Please see the ‘‘Privacy Act’’ paragraph 

below. 

Submitting Comments 

If you submit a comment, please 

include the docket number [USCG– 

2013–0133], indicate the specific 

section of the document to which each 

comment applies, providing a reason for 

each comment. You may submit your 

comments and material online (via 

http://www.regulations.gov), by fax, 

mail, or hand delivery, but please use 

only one of these means. If you submit 

a comment online via 

www.regulations.gov, it will be 

considered received by the Coast Guard 

when you successfully transmit the 

comment. If you fax, hand deliver, or 

mail your comment, it will be 

considered as having been received by 

the Coast Guard when it is received at 

the DMF. We recommend you include 

your name, mailing address, an email 

address, or other contact information in 

the body of your document so that we 

can contact you if we have questions 

regarding your submission. 

You may submit comments and 

material by electronic means, mail, fax, 

or delivery to the DMF at the address 

under ADDRESSES, but please submit 

them by only one means. To submit 

your comment online, go to http:// 

www.regulations.gov, and type ‘‘USCG– 

2013–0133’’ in the ‘‘Keyword’’ box. If 

you submit your comments by mail or 

hand delivery, submit them in an 

unbound format, no larger than 81⁄2 by 

11 inches, suitable for copying and 

electronic filing. If you submit 

comments by mail and would like to 

know that they reached the Facility, 

please enclose a stamped, self-addressed 


emcdonald on DSK67QTVN1PROD with NOTICES